The high-resolution structure reveals remarkable similarity in pd-1 binding of cemiplimab and dostarlimab, the fda-approved antibodies for cancer immunotherapy

HIGHLIGHTS

• who: Tae-Jun Jeong and collaborators from the Department of Chemistry, Konkuk University, Neungdong-ro, Seoul, Republic of Korea have published the paper: The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy, in the Journal: Biomedicines 2022, 3154 of 21/09/2022
• what: The high-resolution structure of PD-1 in complex with the Fab fragment of cemiplimab sheds light on the molecular mechanism underlying the therapeutic activity of this antibody drug.

SUMMARY

PD-1 is a crucial . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.